evt-101 evt-101 evt-101, also known as ens-101, is an experimental medication which originated from roche and is under development by evotec ag for the treatment of major depressive disorder. it acts as a selective nmda receptor subunit 2b (nr2b) antagonist. the drug was first claimed by roche in 2002. by 2017, evt-101 was in phase ii clinical trials for major depressive disorder; however, development of the drug was discontinued in 2021. evt-101clinical dataother namesens-101drug classnmda receptor antagonistidentifiers iupac name 5--3-pyridazine cas number627525-33-1 1166398-51-11189088-41-2 (hcl)pubchem cid22240172chemspider11255877unii14dn1wb87schemblchembl3545350chemical and physical dataformulac16h13f3n4molar mass318.303 g·mol−13d model (jsmol)interactive image smiles cc1=nc=cn1cc2=nn=cc(=c2)c3=cc(=c(c=c3)f)c(f)f inchi inchi=1s/c16h13f3n4/c1-10-20-4-5-23(10)9-13-6-12(8-21-22-13)11-2-3-15(17)14(7-11)16(18)19/h2-8,16h,9h2,1h3key:bovuhbfxpnltkf-uhfffaoysa-n